Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Robert Lenk Biography and Net Worth

Director of Plus Therapeutics

Dr. Robert P. Lenk Ph.D. has been appointed as Independent Director of the Company effective 4/1/2020. Dr. Lenk is President of Link Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has served as Chief Scientific Officer of MediVector, Inc.; President of the NanoWorks division of Luna Innovations, Inc.; President & CEO of Therapeutics 2000, Inc.; and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Lenk was also a Cofounder of The Liposome Co. and a Staff Fellow of the National Institute of Child Health and Human Development. Dr. Lenk has a PhD and BS from the Massachusetts Institute of Technology.

What is Robert P. Lenk's net worth?: The estimated net worth of Robert P. Lenk is at least $26,334.40 as of November 15th, 2023. Mr. Lenk owns 24,160 shares of Plus Therapeutics stock worth more than $26,334 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Lenk may own. Learn More about Robert P. Lenk's net worth.
How do I contact Robert P. Lenk?: The corporate mailing address for Mr. Lenk and other Plus Therapeutics executives is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. Plus Therapeutics can also be reached via phone at 737-255-7194 and via email at [email protected]. Learn More on Robert P. Lenk's contact information.
Has Robert P. Lenk been buying or selling shares of Plus Therapeutics?: Robert P. Lenk has not been actively trading shares of Plus Therapeutics during the last ninety days. Most recently, on Wednesday, November 15th, Robert P. Lenk bought 1,000 shares of Plus Therapeutics stock. The stock was acquired at an average cost of $1.77 per share, with a total value of $1,770.00. Following the completion of the transaction, the director now directly owns 24,160 shares of the company's stock, valued at $42,763.20. Learn More on Robert P. Lenk's trading history.
Who are Plus Therapeutics' active insiders?: Plus Therapeutics' insider roster includes Marc Hedrick (CEO), Robert Lenk (Director), Greg Petersen (Director), and Andrew Sims (CFO). Learn More on Plus Therapeutics' active insiders.
Are insiders buying or selling shares of Plus Therapeutics?: In the last year, Plus Therapeutics insiders bought shares 7 times. They purchased a total of 48,059 shares worth more than $82,744.90. The most recent insider tranaction occured on September, 13th when Director Richard J Hawkins bought 4,000 shares worth more than $6,000.00. Insiders at Plus Therapeutics own 5.5% of the company. Learn More about insider trades at Plus Therapeutics.
Information on this page was last updated on 9/13/2024.

Robert P. Lenk Insider Trading History at Plus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2023	Buy	1,000	$1.77	$1,770.00	24,160
11/13/2023	Buy	4,000	$1.43	$5,720.00	23,160
11/10/2023	Buy	2,000	$1.45	$2,900.00	19,160
11/8/2023	Buy	5,000	$1.65	$8,250.00	12,961
11/6/2023	Buy	1,395	$1.50	$2,092.50	1,961
9/13/2021	Buy	466	$27.90	$13,001.40	666
8/25/2020	Buy	200	$37.35	$7,470.00	200

Robert P. Lenk Buying and Selling Activity at Plus Therapeutics

Plus Therapeutics Company Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Today's Range

Now: $1.09

$0.97

$1.11

50 Day Range

MA: $1.29

$0.99

$1.45

2 Week Range

Now: $1.09

$0.93

$2.67

Volume

48,987 shs

Average Volume

64,415 shs

Market Capitalization

$6.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7